Background Previous studies have suggested that loss of the EGFR T790M gene mutation
may contribute to the development of resistance to Osimertinib in non‐small cell lung cancer …

Background and Purpose: Pervious studies have demonstrated that the loss of EGFR
T790M after Osimertinib treatment may be the cause of Osimertinib resistance. Here, we …

Introduction Osimertinib resistance is inevitable. The purpose of this study was to explore the
predictive value of pretreatment clinical characteristics in T790M-positive non-small cell lung …

Background Osimertinib is a potent third-generation EGFR tyrosine kinase inhibitor (TKI)
with robust activity in advanced EGFR-mutant non-small cell lung cancer (NSCLC) …

Background Osimertinib demonstrates superior efficacy in patients with non-small cell lung
cancer (NSCLC) who acquired EGFR T790M mutation as resistant mechanism to upfront …

Simple Summary Osimertinib is a third-generation epidermal growth factor receptor tyrosine
kinase inhibitor (EGFR-TKI) designed to overcome acquired T790M resistance mutations in …

Background Although with the impressive efficacy, several patients showed intrinsic
resistance or an unsatisfactory response to Osimertinib. We aim to explore the impact of …

Osimertinib is a mutant-selective EGFR inhibitor that is effective against non-small cell lung
cancer (NSCLC) in patients with the EGFR-T790M mutation, who are resistant to EGFR …

Background: Osimertinib efficacy in pre-treated patients with epidermal growth factor
receptor (EGFR) T790M-mutated non-small cell lung cancer (NSCLC) has been …

Purpose: A T790M of the epidermal growth factor receptor (EGFR) is the most frequently
encountered mutation conferring acquired resistance to EGFR tyrosine kinase inhibitors …